High affinity binding of factor XIIa to an electronegative surface controls the rates of factor XII and prekallikrein activation in vitro

Thrombosis Research

Volumn 94, Issue 2, 1999, Pages 117-129

  Mitropoulos, Kostas A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

C1 inhibitor; Contact system of coagulation; Electronegative surface; Factor XII; High molecular weight kininogen; Prekallikrein

Indexed keywords

AMIDE; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; PREKALLIKREIN; SULFATIDE;

ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; ENZYME ACTIVITY; ENZYME INACTIVATION; HYDROLYSIS; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; SURFACE PROPERTY;

ACTIVATION ANALYSIS; ANIMALS; CATTLE; CEREBROSIDES; FACTOR XII; HUMANS; KALLIKREIN-KININ SYSTEM; KININOGENS; PLASMA; PREKALLIKREIN; REGRESSION ANALYSIS;

EID: 0033560671     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00207-2     Document Type: Article

References (42)

1. Wachtfogel Y.T., DeLa Cadena R.A., Colman R.W. Structural biology, cellular interactions and pathophysiology of the contact system. Thromb Res. 72:1993;1-21.
2. Espana F., Ratnoff O.D. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med. 102:1983;31-45.
3. Tans G., Rosing J., Griffin J.H. Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor). J Biol Chem. 258:1983;8215-8222.
4. Tankersley D.L., Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry. 23:1984;273-279.
5. Silverberg M., Dunn J.T., Garen L., Kaplan A.P. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem. 255:1980;7281-7286.
6. Griep M.A., Fujikawa K., Nelsestuen G.L. Binding and activation properties of human factor XII, prekallikrein and derived peptides with acidic lipid vesicles. Biochemistry. 24:1985;4124-4130.
7. Dunn J.T., Silverberg M., Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem. 257:1982;1779-1784.
8. Mitropoulos K.A., Esnouf M.P. The autoactivation of factor XII in the presence of long-chain saturated fatty acids - a comparison with the potency of sulphatides and dextran sulphate. Thromb Haemost. 66:1991;446-452.
9. Ratnoff O.D., Davie E.W., Mallett D.L. Studies on the action of Hageman factor. Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent J Clin Invest. 40:1961;803-819.
10. Rosenthal R.L., Dreskin O.H., Rosenthal N. New haemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 82:1953;171-174.
11. Mitropoulos K.A. Lipid-thrombosis interface. Br Med Bull. 50:1994;813-832.
12. Mandle R. Jr., Colman R.W., Kaplan A.P. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA. 73:1976;4179-4183.
13. Thompson R.E., Mandle R. Jr., Kaplan A.P. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest. 60:1977;1376-1380.
14. Griffin J.H., Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA. 73:1976;2554-2558.
15. Tait J.F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 262:1987;11651-11656.
16. Pixley R.A., Schapira M., Colman R.W. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 260:1985;1723-1729.
17. de Agostini A., Lijnen H.R., Pixley R.A., Colman R.W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest. 73:1984;1542-1549.
18. Schapira M., Scott C.F., Colman R.W. Contribution of plasma protease inhibitors to the inactivations of kallikrein in plasma. J Clin Invest. 69:1982;462-468.
19. Bieth J. Some kinetic consequences of the tight binding of protein proteinase-inhibitors to proteolytic enzymes and their application to the determination of dissociation constants. In: Protease Inhibitors, V. Baayer-Symposium. Berlin: Springer-Verlag; 1974. pp. 463-9.
20. Harpel P.C. Blood proteolytic enzyme inhibitors. Their role in modulating coagulation and fibrinolytic enzyme pathways Colman R.W., Hirsch J., Marder V.J., Salzman E.W. Haemostasis and Thrombosis. 1982;738-747 J.B. Lippincott, Philadelphia.
21. Schmaier A.H. Contact activation. A revision Thromb Haemost. 78:1997;101-107.
22. Colman R.W., Schmaier A.H. Contact system. A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes Blood. 90:1997;3819-3843.
23. Mitropoulos K.A., Reeves B.E.A., Miller G.J. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins. Blood Coagul Fibrinolysis. 4:1993;943-951.
24. Mitropoulos K.A., Miller G.J., Watts G.F., Durrington P.N. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII. A study in familial lipoprotein-lipase deficiency Atherosclerosis. 95:1992;119-125.
25. Tans G., Janssen-Claessen T., Rosing J., Griffin J.H. Studies on the effect of serine protease inhibitors on activated contact factors. Applications in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur J Biochem. 164:1987;637-642.
26. Mitropoulos K.A., Reeves B.E., O'Brien D.P., Cooper J.A., Martin J.C. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coagul Fibrinolysis. 4:1993;223-234.
27. r of the activating polyanion. Biochem J. 248:1987;715-720.
28. Tazi S., Tans G., Hemker H.C., Nigretto J.M. Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight. Thromb Res. 67:1992;665-676.
29. Pixley R.A., Schmaier A., Colman R.W. Effect of negatively charged activating compounds on inactivation of factor XIIa by C1-inhibitor. Arch Biochem Biophys. 256:1987;490-498.
30. Schapira M., Scott C.F., James A., Silver L.D., Kueppers F., James H.L., Colman R.W. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry. 21:1982;567-572.
31. Schapira M., Scott C.F., Colman R.W. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry. 20:1981;2738-2743.
32. Harpel P.C. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med. 132:1970;329-352.
33. Tait J.F., Fujikawa K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity. J Biol Chem. 261:1986;15396-15401.
34. Villanueva G.B., Leung L., Bradford H., Colman R.W. Conformation of high molecular weight kininogen. Effects of kallikrein and factor XIa cleavage Biochem Biophys Res Commun. 158:1989;72-79.
35. Weisel J.W., Nagaswami C., Woodhead J.L., DeLa Cadena R.A., Page J.D., Colman R.W. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem. 269:1994;10100-10106.
36. Hansson C.G., Karlsson K.-A., Samuelsson B.E. The identification of sulphatides in human erythrocyte membrance and their relation to sodium-potassium dependent adenosine triphosphate. J Biol Chem (Tokyo). 83:1978;813-819.
37. Mitropoulos K.A., Martin J.C., Stirling Y., Morrissey J.H., Cooper J.A. Activation of factors XII and VII induced in citrated plasma in the presence of contact surface. Thromb Res. 78:1995;67-75.
38. Mitropoulos K.A., Miller G.J., Reeves B.E.A., Wilkes H.C., Cruickshank J.K. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis. 76:1989;203-208.
39. Elwood P.C., Beswick A.D., O'Brien J.R., Yarnell J.W.G., Layzell J.C., Limb E.S. Inter-relationships between haemostatic tests and the effects of some dietary determinants in the Caerphilly cohort of older men. Blood Coag Fibrinolysis. 4:1993;529-536.
40. Negri M., Arigliano P.L., Talamini G., Carlini S., Manzato F., Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. Atherosclerosis. 99:1993;55-61.
41. Green D., Chamberlain M.A., Ruth K.J., Folsom A.R., Liu K. Factor VII, cholesterol, and triglycerides. The CARDIA study. Coronary artery risk development in young adults study. Arterioscler Thromb Vasc Biol. 17:1997;51-55.
42. Miller G.J., Mitropoulos K.A., Nanjee M.N., Howarth D.J., Martin J.C., Esnouf M.P., Reeves B.E.A., Miller N.E., Cooper J.A. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia. Thromb Haemost. 80:1998;233-238.